MONMOUTH JUNCTION, NJ--(Marketwired - Jan 7, 2014) - CytoSorbents Corporation (
- CytoSorb® is the only specifically approved extracorporeal cytokine filter in the European Union. It is clinically proven to reduce excessive blood levels of cytokines, often called "cytokine storm", which can drive dangerous and deadly widespread inflammation in critically ill patients. This uncontrolled inflammation can rapidly lead to the damage and failure of vital organs, the cause of nearly half of all deaths in the intensive care unit (ICU). The goal of CytoSorb® therapy is to prevent or treat organ failure by reducing severe inflammation in a diverse set of life threatening conditions such as sepsis, lung injury, trauma, burn injury, pancreatitis and others. CytoSorb® is commercially available in multiple European and Asian countries.
- HemoDefend™ - Currently under advanced development, HemoDefend™ is designed to improve the quality and safety of the blood supply by removing non-infectious contaminants such as free hemoglobin, cytokines, bioactive lipids, and antibodies from stored blood products. Many of these contaminants accumulate during blood storage and can cause transfusion reactions and adverse outcomes, including death, in recipients. Critically ill patients, those undergoing high risk surgery such as cardiac surgery, and those receiving multiple blood transfusions such as trauma patients are at particularly high risk for problems. HemoDefend™ is configured as either an in-line point of transfusion filter or as a novel "Beads-in-a-bag" blood storage bag.
Dr. Phillip Chan, MD, PhD, Chief Executive Officer, stated "The initial feedback on our technologies from intensive care unit physicians in the U.S. has been very positive. As we look to expand our CytoSorb® clinical trial activity in the U.S., our goal is to generate even greater awareness amongst a larger universe of physicians and to convey how many of their European counterparts are already using CytoSorb® for multiple ICU applications."
In addition, Dr. Chan will also present at the Biotech Showcase™ 2014 conference on Wednesday, January 15, 2014 in San Francisco. The presentation will take place at 4:00 PM PST in Room Mission II of the Parc 55 Wyndham San Francisco Hotel. Dr. Chan will provide an overview and update on the Company's current status and plans for 2014. He will be joined by Kathleen Bloch, Chief Financial Officer, and Chris Cramer, Vice President of Business Development during the informal question and answer session that will follow. A copy of the presentation will be posted to the Company's website following the conference.
CytoSorb® and HemoDefend™ are not yet United States FDA approved.
The Society of Critical Care Medicine (SCCM) is a non-profit organization that represents nearly 16,000 highly trained professionals in more than 100 countries whose collective goal is to secure the highest quality care for all critically ill and injured patients. The SCCM envisions a day when all such patients are cared for by a dedicated team of physicians, nurses, and other medical professionals specifically trained in critical care. The organization publishes Critical Care Medicine, the premier peer-reviewed, scientific journal in critical care, as well as Pediatric Critical Care Medicine, the first scientific, peer-reviewed journal to focus exclusively on pediatric and neonatal critical care.
About Biotech Showcase™
Biotech Showcase™ 2014 is one of the industry's largest annual healthcare investor and partnering conferences, with more than 1,700 attendees expected. Attendees include biopharmaceutical and life science company executives, investors in private and public companies, sector analysts, bankers and industry professionals. The conference is run concurrently with, but independently from, the JP Morgan Healthcare Conference in San Francisco, one of the largest and most influential international healthcare conferences. Now in its sixth year, the Biotech Showcase™ features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy Colton Life Science Advisors and EBD Group.
About CytoSorbents Corporation
CytoSorbents is a critical care focused immunotherapy company using blood purification to modulate inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com/
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on April 3, 2013, which is available at http://www.sec.gov.